Synageva BioPharma (GEVA +5.1%) gets a kickstart with a timely initiation from Wedbush to Outperform with a price target of $32. Analysts see Phase I/II releases in 2012 building on positive results with the firm's treatment for Wolman disease. Shares of GEVA hit a 52-week high off the momentum.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs